SCHEMBL3065839

SCHEMBL3065839

NCCCCCCCCCCCNC(=O)O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAOX Q6QHF9 4/20 0.64
MAOA P21397 1/20 0.50
MAOB P27338 1/20 0.50
ALDH1A1 P00352 2/20 0.48
ALOX15 P16050 2/20 0.48
MEN1 O00255 1/20 0.48
PLG P00747 1/20 0.48
LMNA P02545 1/20 0.48
THRB P10828 1/20 0.48
SLC6A2 P23975 1/20 0.48
RECQL P46063 1/20 0.48
SLC6A3 Q01959 1/20 0.48
KMT2A Q03164 1/20 0.48
GNAI3 P08754 1/20 0.46
GNAO1 P09471 1/20 0.46
GNAI1 P63096 1/20 0.46
CYP2D6 P10635 1/20 0.44
NFKB1 P19838 1/20 0.44
KDM4E B2RXH2 1/20 0.44
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7004889 1.00 PAOX (0.64) PAOXMAOAMAOBALDH1A1ALOX15
SCHEMBL7010157 1.00 PAOX (0.64) PAOXMAOAMAOBALDH1A1ALOX15
SCHEMBL7007901 1.00 PAOX (0.64) PAOXMAOAMAOBALDH1A1ALOX15
SCHEMBL16247098 1.00 PAOX (0.64) PAOXMAOAMAOBALDH1A1ALOX15
SCHEMBL944344 1.00 PAOX (0.64) PAOXMAOAMAOBALDH1A1ALOX15
SCHEMBL1389554 1.00 PAOX (0.64) PAOXMAOAMAOBALDH1A1ALOX15
SCHEMBL7010487 1.00 PAOX (0.64) PAOXMAOAMAOBALDH1A1ALOX15
Hydrochloric Acid SCHEMBL25353689 0.98 PAOX (0.61) PAOXMAOAMAOBALDH1A1ALOX15
Hydrochloric Acid SCHEMBL15155878 0.98 PAOX (0.61) PAOXMAOAMAOBALDH1A1ALOX15
Ammonia Solution, Strong SCHEMBL8683457 0.98 PAOX (0.61) PAOXMAOAMAOBALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024010776-A1 AGENTS WITH TRANSCRIPTION FACTOR TARGETING MOIETIES BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) 2024-01-11 WO disclosed
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 US disclosed
US-20130060034-A1 ALIPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS WITH BETA AGONIST ACTIVITY JOHNSON MICHAEL ROSS (US) 2013-03-07 US disclosed
US-8324218-B2 Aliphatic pyrazinoylguanidine sodium channel blockers with beta agonist activity PARION SCIENCES, INC. (US) 2012-12-04 US disclosed
US-20100267746-A1 ALIPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS WITH BETA AGONIST ACTIVITY PARION SCIENCES, INC. (US) 2010-10-21 US disclosed
WO-2007146867-A2 ALIPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS WITH BETA AGONIST ACTIVITY PARION SCIENCES INC. (US) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 PAOX 1862/4885MAOA 2771/4885MAOB 2743/4885
US-20100267746-A1 ALIPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS WITH BETA AGONIST ACTIVITY ADRB1, ADRB2, ADRA2B PAOX 488/4885MAOA 800/4885MAOB 401/4885
US-20130060034-A1 ALIPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS WITH BETA AGONIST ACTIVITY SCNN1G, SCNN1B, TRPV1 PAOX 431/4885MAOA 2324/4885MAOB 1413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.